Retatrutide Delivers Remarkable Weight Loss in Landmark Phase 3 Trial
Published: June 2026
A new investigational obesity medication may represent the next major breakthrough in weight management.
Eli Lilly recently announced results from the Phase 3 TRIUMPH-1 clinical trial showing that retatrutide, an experimental once-weekly injection, produced average weight loss approaching 30% of body weight in adults with obesity or overweight. The findings place retatrutide among the most effective weight-loss medications studied to date and approach results traditionally seen with bariatric surgery.
What Is Retatrutide?
Retatrutide is an investigational medication that activates three different hormone receptors involved in appetite and metabolism:
- GLP-1 (glucagon-like peptide-1)
- GIP (glucose-dependent insulinotropic polypeptide)
- Glucagon
Because it targets all three pathways, retatrutide is often referred to as a “triple hormone receptor agonist.” Researchers believe the additional glucagon receptor activity may increase energy expenditure while GLP-1 and GIP reduce appetite and improve blood sugar control.
Impressive Weight Loss Results
The TRIUMPH-1 Phase 3 trial enrolled adults with obesity or overweight and evaluated once-weekly retatrutide over 80 weeks.
The highest dose (12 mg) produced impressive results:
- Average weight loss of 70.3 pounds (28.3%)
- Nearly half of participants (45.3%) lost at least 30% of their starting body weight
- Two-thirds of participants no longer met the definition of obesity by the end of the study
- About one-third reached a body mass index (BMI) below 25, which is considered a healthy weight range.
Researchers also evaluated a subgroup of participants with more severe obesity who continued treatment for 104 weeks. Those individuals achieved an average weight loss of 30.3% (approximately 85 pounds), suggesting benefits continued beyond the original study period.
How Does It Compare With Existing Weight-Loss Medications?
Image shows weight loss results from the clinical trial
Although direct head-to-head studies are still needed, retatrutide has demonstrated greater average weight loss than many currently available medications in separate clinical trials.
Approximate average weight loss reported in major studies includes:
| Medication | Average Weight Loss |
|---|---|
| Lifestyle changes alone | 5–10% |
| Semaglutide | ~15% |
| Tirzepatide | ~21–26% |
| Retatrutide (Phase 3) | 28–30% |
Because these medications were studied in different clinical trials, direct comparisons should be interpreted with caution.
Additional Health Benefits
Beyond weight loss, investigators observed improvements in several obesity-related conditions, including:
- Blood sugar control
- Blood pressure
- Cholesterol levels
- Obstructive sleep apnea
- Knee pain related to osteoarthritis
Separate Phase 3 studies have also shown meaningful improvements in people with type 2 diabetes, including significant reductions in HbA1c while producing substantial weight loss.
What About Side Effects?
As with other medications in the GLP-1 class, the most common side effects were gastrointestinal and included:
- Nausea
- Vomiting
- Diarrhea
- Constipation
Most side effects occurred during dose escalation and were mild to moderate in severity. Higher doses were associated with more gastrointestinal symptoms, although discontinuation rates remained relatively low.
Is Retatrutide FDA Approved?
Not yet.
Although the Phase 3 results are highly encouraging, retatrutide remains an investigational medication and has not yet received FDA approval for weight management or diabetes treatment.
Several additional Phase 3 trials are ongoing to evaluate its long-term safety and effectiveness in different patient populations before regulatory review is complete.
Why These Results Matter
Obesity is a chronic disease that increases the risk of:
- Type 2 diabetes
- Heart disease
- High blood pressure
- Sleep apnea
- Fatty liver disease
- Osteoarthritis
- Certain cancers
Historically, achieving 25–30% weight loss often required bariatric surgery. The results from retatrutide suggest that medication-based treatment may eventually offer similar levels of weight reduction for many patients, representing a significant advance in obesity care.
What Should Patients Know?
While these findings are exciting, retatrutide is still being studied and is not currently available as an FDA-approved treatment.
Patients should also avoid purchasing products marketed as retatrutide online. The FDA has recently warned consumers that some companies are illegally selling unapproved or counterfeit retatrutide products, including products falsely labeled “for research use only.” Until FDA approval is granted, any product claiming to contain retatrutide should be viewed with caution.
References
Eli Lilly. TRIUMPH-1 Phase 3 Trial Results for Retatrutide. May 21, 2026.
American Journal of Managed Care. Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 Trial. May 2026.
ClinicalTrials.gov. TRIUMPH Clinical Trial Program.
Triple–Hormone-Receptor Agonist Retatrutide for Obesity.